FACTOR VIII INHIBITOR BYPASSING ACTIVITY clinical trials

ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX

This study is testing a new medicine, fitusiran, for people with haemophilia A or B. It wants to see how safe and effective it is over a long time, especially in stopping bleeding. Doctors are looking at side effects and how it improves daily life.